NYSE: $JNJ A Breakthrough in Prostate Cancer Research Johnson & Johnson has recently unveiled highly encouraging data regarding its novel therapeutic candidate, JNJ-6420 (often studied in the context of RIPTAC technology). In clinical trials targeting advanced prostate cancer, the drug demonstrated a remarkable 75% tumor response rate, marking a significant milestone for patients facing limited…